HUMA Humacyte (HUMA) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001818382
Cluster · 3 insiders
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
97
13F, latest reported quarter
What the filings say about HUMA
Insiders, 180 days
+$7.6K net bought
3 buyers · 2 sellers · 0% of sales under a 10b5-1 plan
Humacyte insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Humacyte, Inc. insiders bought a net $7.6K of stock across 134 Form 4 purchases and sales, with 3 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Aug 20, 2026.
- The trade is 20.0% of the 50,000 shares held after it.
- No other insider bought within 30 days.
- 97 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Jones Keith Anthony bought about $5.6K of HUMA on Sep 14, 2026; 97 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 17, 2026.
- The trade is 25.0% of the 40,000 shares held after it.
- No other insider bought within 30 days.
- 97 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Jones Keith Anthony bought about $6.9K of HUMA on Aug 20, 2026; 97 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 30,000 shares held after it.
- No other insider bought within 30 days.
- 97 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Jones Keith Anthony bought about $17.8K of HUMA on Aug 17, 2026; 97 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (1 buy, 2 sales), the last on Apr 8, 2025.
- The trade is 38.4% of the 148,025 shares held after it.
- 1 other insider bought within 30 days.
- 97 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Sebelius Kathleen bought about $50.0K of HUMA on May 19, 2026, the largest insider purchase at the company since 2025; 1 other insider bought within 30 days and 97 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 buys), the last on Apr 7, 2025.
- -12.1% median (-5.4% mean) 90-day return after 6 previous buys.
- The trade is 25.0% of the 43,950 shares held after it.
- 1 other insider bought within 30 days.
- 97 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Constantino Michael T. bought about $9.8K of HUMA on May 18, 2026, the largest insider purchase at the company since 2025; 1 other insider bought within 30 days and 97 funds added in the latest 13F quarter.134 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$7.6K over 180 days
+$30.4K over 90 days
more than 66% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
97 funds bought in last quarter
more than 67% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
-2003.6% net margin
below 91% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
11.7% of the float short (float per yahoo 2026-10-26) · 7.3 days to cover · settled 2026-09-30
more than 73% of Pharma & Biotech
The situation: each line is one rule over one dataset
3 insiders independently bought a net $7.6K while the stock fell 38% over six months, with no planned sales queued.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch HUMA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-73.1%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns HUMA: institutional holders (13F)
13F holdings, latest reported quarter
10,103,647 sh
$7.9M
10,107,679 sh
$7.9M
6,022,925 sh
$4.7M
5,000,000 sh
$3.9M
4,839,929 sh
$3.8M
Congress trades in HUMA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
HUMA planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
HUMA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Modern Capital Tactical Income Fund
$460.1K position · as of 2026-06-30
0.7%
Ultra-Small Company Market Fund
$124.9K position · as of 2026-06-30
0.1%
Invesco Nasdaq Biotechnology ETF
$13.2K position · as of 2026-05-31
0.0%
ProShares Ultra Nasdaq Biotechnology
$9.3K position · as of 2026-05-31
0.0%
iShares Biotechnology ETF
$1.1M position · as of 2026-06-30
0.0%
VANGUARD RUSSELL 2000 VALUE INDEX FUND
$125.8K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
14 registered trials, 4 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
3
Phase 2
1 active
4
Phase 3
2 active
1
Phase 4
1 active
5
Not applicable
0 active
1
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$5.2M
-$725.0K
$2.1M
-66%
n/a
2024
$905.4K
$2.9M
$678.0K
+78%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
3 insiders reported buying shares.
The record shows a net $7.6K bought by insiders over 180 days, 97 funds added last quarter. Each figure is a federal filing, dated the day it went public.
HUMA financials
Net margin
-2003.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.1M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM HUMA
| FY Dec 2025 | $2.0M |
| FY Dec 2024 | $0 |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $406.0K |
| Mar 2026 | $495.0K |
| Dec 2025 | $467.0K |
| Sep 2025 | $753.0K |
| Jun 2025 | $301.0K |
| Mar 2025 | $517.0K |
| Dec 2024 | $0 |
| Sep 2024 | $0 |
At each fiscal year end
Single quarter
Net margin, TTM
-4,561%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM HUMA
| FY Dec 2025 | -2,004% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -9,065% |
| Mar 2026 | -3,559% |
| Dec 2025 | -5,311% |
| Sep 2025 | -2,325% |
| Jun 2025 | -12,511% |
| Mar 2025 | +7,570% |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$97.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM HUMA
| FY Dec 2025 | -$105.9M |
| FY Dec 2024 | -$99.7M |
| FY Dec 2023 | -$75.6M |
| FY Dec 2022 | -$72.2M |
| FY Dec 2021 | -$81.4M |
| Jun 2026 | -$22.2M |
| Mar 2026 | -$25.3M |
| Dec 2025 | -$26.2M |
| Sep 2025 | -$24.0M |
| Jun 2025 | -$27.0M |
| Mar 2025 | -$28.8M |
| Dec 2024 | -$26.6M |
| Sep 2024 | -$23.8M |
At each fiscal year end
Single quarter
Debt to equity
1.16x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity HUMA
| FY Dec 2025 | 11.40x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 2.21x |
| FY Dec 2022 | 0.26x |
| FY Dec 2021 | 0.25x |
| Jun 2026 | 1.16x |
| Mar 2026 | 3.09x |
| Dec 2025 | 11.40x |
| Sep 2025 | n/a |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-2.68x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt HUMA
| FY Dec 2025 | -2.96x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -2.44x |
| FY Dec 2022 | -2.37x |
| FY Dec 2021 | -2.71x |
| Jun 2026 | -2.68x |
| Mar 2026 | -2.83x |
| Dec 2025 | -2.96x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -3.02x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-547.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity HUMA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -169.8% |
| FY Dec 2022 | -10.0% |
| FY Dec 2021 | n/a |
| Jun 2026 | -547.9% |
| Mar 2026 | -409.5% |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | -249.8% |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-69.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets HUMA
| FY Dec 2025 | -32.1% |
| FY Dec 2024 | -111.8% |
| FY Dec 2023 | -66.6% |
| FY Dec 2022 | -4.9% |
| FY Dec 2021 | -13.5% |
| Jun 2026 | -69.9% |
| Mar 2026 | -71.5% |
| Dec 2025 | -32.1% |
| Sep 2025 | -35.8% |
| Jun 2025 | -42.3% |
| Mar 2025 | -47.9% |
| Dec 2024 | -111.8% |
| Sep 2024 | -115.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital HUMA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-92.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed HUMA
| FY Dec 2025 | -100.2% |
| FY Dec 2024 | -100.5% |
| FY Dec 2023 | -67.9% |
| FY Dec 2022 | -36.8% |
| FY Dec 2021 | -43.8% |
| Jun 2026 | -92.3% |
| Mar 2026 | -96.2% |
| Dec 2025 | -100.2% |
| Sep 2025 | -131.9% |
| Jun 2025 | -93.4% |
| Mar 2025 | -76.6% |
| Dec 2024 | -100.5% |
| Sep 2024 | -98.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing HUMA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$77.3M
market value at close 2026-10-23 on 2026-08-10 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value HUMA
| FY Dec 2025 | $164.9M |
| FY Dec 2024 | $590.7M |
| FY Dec 2023 | $243.7M |
| FY Dec 2022 | $97.8M |
| FY Dec 2021 | $559.3M |
| Jun 2026 | $129.6M |
| Mar 2026 | $122.1M |
| Dec 2025 | $164.9M |
| Sep 2025 | $256.1M |
| Jun 2025 | $286.2M |
| Mar 2025 | $201.6M |
| Dec 2024 | $590.7M |
| Sep 2024 | $658.7M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-80.7%
TTM free cash flow over market value at close 2026-10-23
FCF yield HUMA
| FY Dec 2025 | -58.9% |
| FY Dec 2024 | -15.7% |
| FY Dec 2023 | -25.7% |
| FY Dec 2022 | -33.2% |
| FY Dec 2021 | -10.9% |
| Jun 2026 | -56.3% |
| Mar 2026 | -76.0% |
| Dec 2025 | -58.9% |
| Sep 2025 | -38.6% |
| Jun 2025 | -32.8% |
| Mar 2025 | -38.1% |
| Dec 2024 | -15.7% |
| Sep 2024 | -14.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing HUMA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $2.0M | $0 | n/a | n/a |
| Operating income | -$108.1M | -$114.4M | -$100.0M | -$84.6M |
| Net income | -$40.8M | -$148.7M | -$110.8M | -$12.0M |
| EPS (diluted) | -0.26 | -1.26 | -1.07 | -0.12 |
| Operating cash flow | -$105.0M | -$98.1M | -$73.3M | -$71.1M |
| Cash | $50.5M | $44.9M | $80.4M | $149.8M |
| Long-term debt | $35.4M | $0 | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-27
HUMA Stock Sonar score 5/7 axes
Find similar shapesCompareHUMA ranks highest on insider conviction (76th percentile) and institutional and government (54th), and lowest on profitability (23rd), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
HUMA filings, in plain words
Are Humacyte insiders buying or selling HUMA?
In the 180 days to 2026-10-27, Humacyte insiders were net buyers, a net $7.6K: $90.2K of purchases and $82.6K of sales reported on Form 4, by 3 buyers and 2 sellers.
Read the full summary
In the 180 days to 2026-10-27, Humacyte insiders were net buyers of HUMA, a net $7.6K across purchases and sales reported on Form 4 by 3 buyers and 2 sellers. 3 insiders reported purchases in that window. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
